©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 28, 2024; 30(8): 806-810
Published online Feb 28, 2024. doi: 10.3748/wjg.v30.i8.806
Published online Feb 28, 2024. doi: 10.3748/wjg.v30.i8.806
Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era
Jian-Hong Zhong, Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Author contributions: Zhong JH wrote and revised the manuscript.
Supported by the Specific Research Project of Guangxi for Research Bases and Talents , No. GuiKe AD22035057 ; and the National Natural Science Foundation of China , No. 82060510 and No. 82260569 .
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Corresponding author: Jian-Hong Zhong, Doctor, PhD, Academic Editor, Doctor, Professor, Surgeon, Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, No. 71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Received: December 10, 2023
Peer-review started: December 10, 2023
First decision: December 27, 2023
Revised: December 27, 2023
Accepted: January 31, 2024
Article in press: January 31, 2024
Published online: February 28, 2024
Processing time: 77 Days and 21.6 Hours
Peer-review started: December 10, 2023
First decision: December 27, 2023
Revised: December 27, 2023
Accepted: January 31, 2024
Article in press: January 31, 2024
Published online: February 28, 2024
Processing time: 77 Days and 21.6 Hours
Core Tip
Core Tip: Several questions need to be addressed by clinical researchers about the use of adjuvant therapy to prolong recurrence-free survival of patients with hepatocellular carcinoma following potentially curative treatment.